INO

Peers: PGEN PDSB ARCT ENGN MRNA OCGN TNXP ANIX GNLX NVAX

Index	-
Market Cap	150.44M
Enterprise Value	121.77M
Income	-67.43M
Sales	0.00M
Book/sh	0.05
Cash/sh	0.35
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	112
IPO	Dec 08, 1998

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	27.41
P/C	4.10
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	1.00
Current Ratio	1.00
Debt/Eq	1.83
LT Debt/Eq	1.17
Option/Short	Yes / Yes

EPS (ttm)	-1.18
EPS next Y	-0.41
EPS next Q	-0.20
EPS this Y	57.09%
EPS next Y	46.78%
EPS next 5Y	61.91%
EPS past 3/5Y	49.51% 32.44%
Sales past 3/5Y	-81.47% -61.18%
EPS Y/Y TTM	54.89%
Sales Y/Y TTM	-100.00%
EPS Q/Q	87.83%
Sales Q/Q	-
Earnings	Nov 10 AMC
EPS/Sales Surpr.	67.70% -

Insider Own	0.38%
Insider Trans	0.00%
Inst Own	38.97%
Inst Trans	1.65%
ROA	-114.64%
ROE	-409.87%
ROIC	-711.67%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	35.36%
SMA50	24.20%
SMA200	14.95%
Trades

Shs Outstand	103.40M
Shs Float	103.01M
Short Float	20.68%
Short Ratio	2.26
Short Interest	21.30M
52W High	2.72 -46.51%
52W Low	0.56 158.35%
Volatility	36.36% 17.43%
ATR (14)	0.25
RSI (14)	57.83
Beta	1.79
Rel Volume	1.68
Avg Volume	9.41M
Volume	10,292,863

Perf Week	88.52%
Perf Month	25.97%
Perf Quarter	117.81%
Perf Half Y	6.20%
Perf YTD	-16.38%
Perf Year	-36.46%
Perf 3Y	-69.30%
Perf 5Y	-98.19%
Perf 10Y	-98.09%
Recom	1.00
Target Price	5.33
Prev Close	1.62
Price	1.46
Change %	-10.19%

Consensus

Strong Buy

Avg. Price Target

$5.33

Implied Upside

+266.3%

Analysts10incl. previous ratings

Rating Distribution5 Buy · 3 Hold · 2 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Nov 02, 2026	Upgrade	HH.C. Wainwright	Neutral → Buy	$5	+243.6%
Aug 13, 2026	Upgrade	JJefferies	Hold → Buy	$3	+106.2%
Jul 09, 2025	Initiated	PPiper Sandler	Overweight	$5	+243.6%
May 14, 2024	Initiated	SStephens	Overweight	$20	+1,274.6%
Jan 25, 2024	Upgrade	OOppenheimer	Perform → Outperform	$4	+174.9%
Nov 09, 2022	Downgrade	MMaxim Group	Buy → Hold
Nov 01, 2022	Downgrade	BBofA Securities	Neutral → Underperform	$2	+37.5%
Jul 19, 2022	Resumed	RRBC Capital Mkts	Sector Perform	$5 → $4	+174.9%
May 11, 2022	Downgrade	OOppenheimer	Outperform → Perform
Jan 21, 2022	Upgrade	BBofA Securities	Underperform → Neutral	$8 → $10	+587.3%
Dec 29, 2021	Resumed	JJefferies	Hold	$8 → $6	+312.4%
Sep 10, 2021	Downgrade	BBofA Securities	Neutral → Underperform	$9 → $8	+449.8%
Jun 24, 2021	Initiated	JJefferies	Hold	$9	+518.6%
Mar 23, 2021	Initiated	BBofA Securities	Neutral	$13	+793.5%
Feb 12, 2021	Initiated	OOppenheimer	Outperform	$35	+2,305.5%
Nov 17, 2020	Downgrade	RROTH Capital	Neutral → Sell
Nov 10, 2020	Upgrade	RROTH Capital	Sell → Neutral	$8	+449.8%
Sep 28, 2020	Upgrade	MMaxim Group	Hold → Buy	$20	+1,274.6%
Sep 28, 2020	Downgrade	CCantor Fitzgerald	Overweight → Neutral
Jul 01, 2020	Downgrade	RROTH Capital	Neutral → Sell	$11	+656.0%

Nov-03-26 02:30PM	Inovio's First Report After Its INO3107 Decision Date Puts Launch Readiness And Cash In Focus (Earnings Whispers) -12.17%
11:36AM	4 Biotech Stocks Seeing Unusual Options Volume Today (Schaeffer's Research)
Nov-02-26 04:15PM	INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026 (PR Newswire) +213.75%
04:01PM	INOVIO to Participate in Upcoming Scientific Conferences (PR Newswire)
01:30PM	Inovio shares surge 229% as FDA approves first commercial product (Proactive)
10:54AM	Loading…
10:54AM	INOVIO Receives FDA Accelerated Approval for VOCERYQ to Reduce Surgery Frequency in Adults with RRP (InvestorsHub)
Oct-30-26 06:01PM	INOVIO Announces FDA Accelerated Approval of VOCERYQ, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) (PR Newswire) -21.95%
Oct-20-26 04:05PM	INOVIO Announces Favorable Judgment in Litigation with VGXI, Inc. and GeneOne Life Science (PR Newswire) -21.26%
Sep-01-26 04:05PM	INOVIO to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-13-26 01:03AM	Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ... (GuruFocus.com) +16.90%
Aug-12-26 04:10PM	Inovio: Q2 Earnings Snapshot (Associated Press)
04:05PM	INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights (PR Newswire)
Aug-04-26 04:05PM	INOVIO to Report Second Quarter Financial Results on August 12, 2026 (PR Newswire)
Jul-29-26 08:53PM	INOVIO Announces Pricing of $20.0 Million Public Offering (PR Newswire) -36.92%
04:01PM	INOVIO Announces Proposed Public Offering (PR Newswire)
08:05AM	Loading…
May-28-26 08:05AM	INOVIO to Participate in Upcoming Scientific and Investor Conferences (PR Newswire)
May-21-26 05:37PM	INO Stock Edges Up After Hours As Partner Reports Success In Cervical Dysplasia Trial (Stocktwits) +8.13%
04:05PM	Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China (PR Newswire)
May-14-26 01:02AM	Inovio Pharmaceuticals Inc (INO) Q1 2026 Earnings Call Highlights: Progress and Challenges in ... (GuruFocus.com)
May-13-26 04:13PM	Inovio: Q1 Earnings Snapshot (Associated Press)
04:05PM	INOVIO Reports First Quarter 2026 Financial Results and Recent Business Highlights (PR Newswire)
May-08-26 08:05AM	INOVIO to Participate in Upcoming Scientific Conferences (PR Newswire) +6.57%
May-01-26 04:05PM	INOVIO to Report First Quarter Financial Results on May 13, 2026 (PR Newswire)
Apr-02-26 08:55AM	INOVIO Announces Pricing of $17.5 Million Public Offering (PR Newswire) -35.06%
Apr-01-26 08:05PM	INOVIO Announces Proposed Public Offering (PR Newswire)
10:29AM	INOVIO to Participate in Upcoming Scientific Conference (PR Newswire)
Mar-30-26 03:47AM	Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO (PR Newswire)
Mar-12-26 11:07PM	Inovio Pharmaceuticals Inc (INO) Q4 2025 Earnings Call Highlights: Strategic Moves and ... (GuruFocus.com)
04:47PM	Inovio: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (PR Newswire)
08:05AM	Loading…
Mar-09-26 08:05AM	INOVIO to Participate in Upcoming Scientific Conferences (PR Newswire)
Mar-05-26 04:05PM	INOVIO to Report Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 (PR Newswire)
Mar-04-26 09:00AM	LEVI & KORSINSKY, LLP: INO SHARES DECLINE 24% AS FDA REVIEW CLASSIFICATION REVEALS ALLEGED REGULATORY SETBACK (PR Newswire)
08:05AM	INOVIO and Akeso Announce Clinical Collaboration to Advance Novel Combination Therapy for Glioblastoma (GBM) (PR Newswire)
Feb-26-26 09:16AM	Inovio Pharmaceuticals Spotlights INO-3107 BLA Acceptance, FDA Talks Ahead of Oct. 30 PDUFA Date (MarketBeat)
Feb-25-26 09:00AM	LEVI & KORSINSKY, LLP: SECTION 10(B) AND RULE 10B-5 CLAIMS ASSERTED IN INOVIO PHARMACEUTICALS SECURITIES LITIGATION (PR Newswire)
Feb-20-26 04:27AM	Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - INO (PR Newswire)
Feb-12-26 08:05AM	INOVIO to Participate in Upcoming Scientific and Investor Conferences (PR Newswire)
07:30AM	Inovio Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights INO (Business Wire)
Dec-30-25 08:10AM	Inovio announces U.S. FDA accepted BLA for INO-3107 (TipRanks)
Dec-29-25 08:05AM	FDA Accepts for Review INOVIO's BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP) (PR Newswire) -24.45%
Dec-19-25 04:05PM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire)
Nov-18-25 08:05AM	INOVIO to Participate in December Investor Conferences (PR Newswire)
Nov-14-25 12:00PM	Inovio (INO) Upgraded to Buy: Here's Why (Zacks) +5.13%
Nov-11-25 08:40AM	INOVIO Announces Pricing of $25 Million Public Offering (PR Newswire) -6.98%
12:00AM	Inovio Pharmaceuticals Inc (INO) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Nov-10-25 06:09PM	INOVIO Announces Proposed Public Offering (PR Newswire)
04:17PM	Inovio: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports Third Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
Nov-03-25 08:05AM	INOVIO Completes Rolling BLA Submission Seeking Accelerated Approval for INO-3107 as a Treatment for RRP in Adults (PR Newswire) +6.38%
Oct-31-25 04:53PM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire)
Oct-27-25 08:05AM	INOVIO to Report Third Quarter 2025 Financial Results on November 10, 2025 (PR Newswire) +6.87%
Oct-23-25 04:05PM	INOVIO to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference (PR Newswire)
Oct-21-25 08:05AM	Clinical Proof-of-Concept Data for DNA-Encoded Monoclonal Antibodies (DMAbs) Published in Nature Medicine (PR Newswire) -5.67%
Oct-02-25 08:05AM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire)
Sep-25-25 08:05AM	INOVIO to Participate in Upcoming Scientific Conferences (PR Newswire)
Aug-28-25 10:00AM	INO Stock Soars as FDA Backs Rolling BLA for Rare Lung Disease Drug (Zacks)
Aug-26-25 08:05AM	INOVIO to Begin Rolling Submission of BLA for INO-3107 for the Treatment of RRP in Adults (PR Newswire)
Aug-25-25 11:04AM	PGEN Stock Surges 144% in August on FDA Nod for Rare Lung Disease Drug (Zacks)
08:05AM	INOVIO to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-14-25 12:22PM	Cancer Treatment Stocks Surge as $866B Market Attracts Private Investment (PR Newswire)
Aug-13-25 03:11AM	Inovio Pharmaceuticals Inc (INO) Q2 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) +14.09%
Aug-12-25 04:20PM	Inovio: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports Second Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
Aug-11-25 06:55PM	Agenus (AGEN) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
09:10AM	3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates (Zacks)
08:05AM	Data Published in The Laryngoscope shows INO-3107 Resulted in Long-Term Surgery Reduction in Recurrent Respiratory Papillomatosis (RRP) (PR Newswire)
Aug-07-25 10:00AM	Earnings Preview: Dianthus Therapeutics, Inc. (DNTH) Q2 Earnings Expected to Decline (Zacks)
Aug-05-25 10:00AM	Inovio Pharmaceuticals (INO) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Aug-04-25 04:05PM	INOVIO to Report Second Quarter 2025 Financial Results on August 12, 2025 (PR Newswire)
Jul-07-25 04:05PM	INOVIO to Present at Upcoming Scientific Conference (PR Newswire)
Jul-03-25 07:30AM	INOVIO Announces Pricing of $25 Million Public Offering (PR Newswire) -37.85%
Jul-02-25 04:16PM	INOVIO Announces Proposed Public Offering (PR Newswire)
Jul-01-25 07:00AM	Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development (GlobeNewswire)
May-14-25 12:43PM	Q1 2025 Inovio Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:15AM	Inovio Pharmaceuticals Inc (INO) Q1 2025 Earnings Call Highlights: Strategic Cost Management ... (GuruFocus.com)
May-13-25 05:40PM	Inovio Pharmaceuticals (INO) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:39PM	Inovio: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
Apr-30-25 08:05AM	INOVIO to Present at Upcoming Scientific and Investor Conferences (PR Newswire)
Apr-29-25 08:05AM	INOVIO to Report First Quarter 2025 Financial Results on May 13, 2025 (PR Newswire)
Apr-21-25 07:40AM	Bet on These 5 Top-Ranked Stocks With Rising P/E (Zacks)
Apr-09-25 12:00PM	Inovio (INO) Upgraded to Buy: Here's What You Should Know (Zacks) +8.90%
08:05AM	INOVIO to Present at Upcoming Scientific Conferences (PR Newswire)
Apr-01-25 09:35AM	Down -11.41% in 4 Weeks, Here's Why You Should You Buy the Dip in Inovio (INO) (Zacks) -7.98%
Mar-19-25 03:02AM	Inovio Pharmaceuticals Inc (INO) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -6.67%
Mar-18-25 10:15PM	Inovio Pharmaceuticals (INO) Q4 2024 Earnings Call Transcript (Motley Fool)
04:05PM	INOVIO Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights (PR Newswire)
Mar-13-25 06:15PM	INOVIO Announces Promising Interim Results from Ongoing Proof-of-Concept Clinical Trial of DNA-Encoded Monoclonal Antibodies (DMAbs) for COVID-19 (PR Newswire) -5.85% +5.18%
Mar-12-25 12:55PM	INOVIO to Report Fourth Quarter and Year End 2024 Financial Results on March 18, 2025 (PR Newswire) +5.13%
Feb-12-25 09:55AM	Here's Why Inovio (INO) Could be Great Choice for a Bottom Fisher (Zacks) +12.11%
08:00AM	Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications (PR Newswire)
Feb-10-25 08:05AM	Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference (PR Newswire)
Jan-29-25 04:14PM	INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference (PR Newswire) -7.31%
Jan-09-25 08:04AM	INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments (PR Newswire)
Dec-13-24 07:00AM	INOVIO Announces Pricing of $30 Million Public Offering (PR Newswire) -38.30%
Dec-12-24 04:01PM	INOVIO Announces Proposed Public Offering (PR Newswire) -6.58%
Dec-03-24 08:00AM	New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial (PR Newswire)
Nov-29-24 04:02PM	INOVIO Reports Inducement Grant Under Inducement Plan (PR Newswire)
Nov-15-24 02:15AM	Inovio Pharmaceuticals Inc (INO) Q3 2024 Earnings Call Highlights: Progress in INO-3107 ... (GuruFocus.com) -10.59%

Show Previous News

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

CEODr. Jacqueline E. Shea Ph.D.

Chief Financial OfficerMr. Peter D. Kies

M.B.A.Dr. Michael Sumner B.S.

Chief Scientific Officer & Chairman of the Scientific Advisory BoardDr. Laurent M. Humeau Ph.D.

General CounselMr. Robert L. Crotty J.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Inovio Pharmaceuticals Inc

Upgrade your Finviz experience